Innoviva, Inc. (INVA) Social Stream



Innoviva, Inc. (INVA): $14.95

0.26 (+1.77%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

B

Add INVA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#27 of 362

in industry

Featured Post From StockTwits About INVA

$INVA From the 7/28 Q2 ER - also has investments in ARMP and a $300M SPAC:

Capital Allocation:
In May 2021, the Company repurchased 32,005,260 shares of its common stock from GSK at $12.25 per share for a total amount (including related transaction fees) of $394.1 million. The repurchased shares represented all of GSK’s equity stake in the Company, which was approximately 32% of the Company’s shares.

During the second quarter of 2021, the Company’s wholly owned subsidiary, Innoviva Strategic Opportunities LLC, invested $20.0 million to acquire 10 million shares of Entasis’ common stock and warrants to purchase up to an additional 10 million shares of common stock at $2.00 per share. With this additional investment, Innoviva collectively owned approximately 60.6% of Entasis’ common stock as of June 30, 2021 in addition to the warrants.
raylin, published August 13, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!